In early look at ASH abstracts, BeiGene touts Brukinsa data, Cellectis compares in-house CAR-T to CDMO CAR-T

Max Gelman

Senior Editor

The non-late breaking abstracts for next month’s American Society of Hematology meeting were released on Thursday, giving a peek into what will be some of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In early look at ASH abstracts, BeiGene touts Brukinsa data, Cellectis compares in-house CAR-T to CDMO CAR-T

Max Gelman

Senior Editor

Sign up to read this article for free.

Updated: Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health ...

David Baker's lab makes enzymes with AI, opening up the possibility of more precise gene-editing tools

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

In ear­ly look at ASH ab­stracts, BeiGene touts Brukin­sa da­ta, Cel­lec­tis com­pares in-house CAR-T to CD­MO CAR-T

Max Gelman

Senior Editor

Sign up to read this article for free.

Up­dat­ed: Kennedy is con­firmed to lead HHS, putting an­ti-vac­cine ad­vo­cate and drug in­dus­try skep­tic atop US health ...

David Bak­er's lab makes en­zymes with AI, open­ing up the pos­si­bil­i­ty of more pre­cise gene-edit­ing tools

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Agios’ Pyrukynd suc­ceeds in key tri­al of rare red blood cell dis­or­der in kids

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

In early look at ASH abstracts, BeiGene touts Brukinsa data, Cellectis compares in-house CAR-T to CDMO CAR-T

Updated: Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health ...

David Baker's lab makes enzymes with AI, opening up the possibility of more precise gene-editing tools

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kids

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers